Hepatitis - Clinical Care Options

HCV Phase III Studies and Approved Agents

In this downloadable slideset, Paul Y. Kwo, MD; David R. Nelson, MD; and Stefan Zeuzem, MD, review results from HCV phase III trials and key studies of approved HCV agents from the 2013 European Association for the Study of Liver.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/13/2013
HCV Phase III Studies and Approved Agents

In this downloadable slideset, Paul Y. Kwo, MD; David R. Nelson, MD; and Stefan Zeuzem, MD, review results from HCV phase III trials and key studies of approved HCV agents from the 2013 European Association for the Study of Liver.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/13/2013
MK-5172 Plus PegIFN/RBV Achieves 86% to 92% SVR24 Rates in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV

91% of patients receiving MK-5172 100 mg/day were eligible for shortened (24-week) duration of therapy, of whom 90% achieved SVR24.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/7/2013
High SVR12 Rates With Short-Course (6 or 12 Weeks) of Ledipasvir and GS-9451 Plus PegIFN/RBV Quadruple Therapy in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV Infection and IL28B CC Genotype

92% of patients achieved early virologic response and were eligible for short-course therapy; SVR12 rates were 98% with 12 weeks vs 79% with 6 weeks of quadruple therapy.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/6/2013
Vaniprevir Plus PegIFN/RBV Significantly Increases SVR24 Rate vs PegIFN/RBV Retreatment in Cirrhotic, Genotype 1 HCV–Infected, Previous Nonresponders to PegIFN/RBV

Vaniprevir-based therapy generally well tolerated, with increased incidence of mild to moderate gastrointestinal adverse events.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/6/2013
Daclatasvir Plus Asunaprevir Plus BMS-791325 Achieves ≥ 88% SVR Rates in Noncirrhotic Treatment-Naive Patients With Genotype 1 HCV

The all-oral regimen combining an NS5a inhibitor, a protease inhibitor, and a nonnucleoside polymerase inhibitor was well tolerated at both doses of BMS-791325 studied.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/3/2013
HBV DNA Seroclearance Significantly Reduces Risk of HCC in Patients With High Baseline Viral Loads

Seroclearance of HBeAg, HBsAg did not significantly decrease HCC risk in adjusted analysis.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/2/2013
CONCISE: Interim Results Show High SVR Rates With Either 12 or 24 Weeks of Telaprevir Plus Peginterferon/Ribavirin in Patients With HCV Genotype 1 and IL28B CC Genotype

Among patients who completed 12 weeks of triple therapy, 100% SVR12 rate among patients who continued to receive peginterferon/ribavirin through 24 weeks vs 89% SVR4 rate among patients who stopped all therapy at 12 weeks.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/2/2013
QUEST-1: Simeprevir Plus PegIFN/RBV Significantly Improves SVR12 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV

Triple therapy was well tolerated and 85% of patients were able to shorten treatment to 24 weeks, of whom 91% achieved SVR12.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 5/1/2013
COMMAND: Daclatasvir Plus PegIFN/RBV Improves SVR24 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 2/3 HCV

The triple-drug regimen allowed 83% of patients to receive shorter treatment durations of only 12 or 16 weeks, and safety and tolerability was comparable to pegIFN/RBV alone.

Source: 2013 Annual Meeting of the European Association for the Study of the Liver

Date Posted: 4/30/2013

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Latest Content

HCV Phase III Studies and Approved Agents

HCV Phase III Studies and Approved Agents

MK-5172 Plus PegIFN/RBV Achieves 86% to 92% SVR24 Rates in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV

High SVR12 Rates With Short-Course (6 or 12 Weeks) of Ledipasvir and GS-9451 Plus PegIFN/RBV Quadruple Therapy in Treatment-Naive, Noncirrhotic Patients With Genotype 1 HCV Infection and IL28B CC Genotype

Vaniprevir Plus PegIFN/RBV Significantly Increases SVR24 Rate vs PegIFN/RBV Retreatment in Cirrhotic, Genotype 1 HCV–Infected, Previous Nonresponders to PegIFN/RBV

Daclatasvir Plus Asunaprevir Plus BMS-791325 Achieves ≥ 88% SVR Rates in Noncirrhotic Treatment-Naive Patients With Genotype 1 HCV

HBV DNA Seroclearance Significantly Reduces Risk of HCC in Patients With High Baseline Viral Loads

CONCISE: Interim Results Show High SVR Rates With Either 12 or 24 Weeks of Telaprevir Plus Peginterferon/Ribavirin in Patients With HCV Genotype 1 and IL28B CC Genotype

QUEST-1: Simeprevir Plus PegIFN/RBV Significantly Improves SVR12 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 1 HCV

COMMAND: Daclatasvir Plus PegIFN/RBV Improves SVR24 Rate vs PegIFN/RBV Alone in Treatment-Naive Patients With Genotype 2/3 HCV

Filter Content By

CCO Live Meetings